Clinical Trial Update: A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS [Phase 2]

View source ↗

Summary

Phase 2 study assessing safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with STEC-HUS has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea-associated Hemolytic Uremic Syndrome
• Hemolytic Uremic Syndrome
• Kidney Disease

Drugs mentioned

• INM004

Snippet

Sponsor: Inmunova S.A. | Conditions: Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Status: COMPLETED